Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

SANUWAVE Technology Shown to Proliferate Adult Stem Cells

December 14, 2011 By AxoGen, Inc.

ALPHARETTA, Ga.–(BUSINESS
WIRE
)–SANUWAVE Health, Inc., an emerging medical technology
company focused on the development and commercialization of noninvasive,
biological response activating devices in regenerative medicine, today
announced the publication of peer-reviewed, preclinical data that demonstrate
the ability of the Companys extracorporeal shock wave technology (ESWT) to
substantially stimulate proliferation of periosteal progenitor/adult stem cells
within the body and significantly increase the quantity and quality of adult
stem cells that can be harvested from the cambium layer (the inner osteogenic
layer of the periosteum) for select tissue engineering and regenerative
medicine applications.

The authors demonstrated that ESWT effectively proliferates
adult stem cells within the periosteum of femurs and tibias in a rodent model,
which the authors suggest could then be more efficiently harvested and
transplanted for orthopaedic applications, such as fracture or joint repair and
human tissue engineering applications. The publication, titled “Extracorporeal
Shock Wave-Induced Proliferation of Periosteal Cells,” appears in a recent
edition of the Journal of Orthopaedic Research.

An abstract of the publication can be accessed online at the
Journal of Orthopaedic Research website: http://onlinelibrary.wiley.com/doi/10.1002/jor.21346/abstract.

Summary of Key Study Findings

  • In the tibia, four days after a single treatment, ESWT resulted in a six-fold
    increase in the number of adult stem cells within the cambium layer and an
    eight-fold increase in cambium layer thickness. In the femur, also at four days
    following treatment, ESWT resulted in a three-fold increase in the number of
    adult stem cells and nearly a five-fold increase in the thickness of the
    cambium layer.
  • The ESWT energy levels used to stimulate the proliferation of
    adult stems cell did not damage surrounding tissues.
  • The elevated presence of certain proteins at the treatment
    site suggests that ESWT promotes rapid vascularization of bone.
  • ESWT has the potential to be a noninvasive, fast, safe and
    relatively inexpensive way to stimulate periosteal adult stem cell
    proliferation within the human body that may be harvested for select tissue
    engineering and regenerative medicine applications.

Led by Myron Spector, M.D., a professor and researcher at
Harvard-MIT Division of Health Sciences and Technology, the authors concluded,
“This study successfully demonstrated the use of ESWT as a non-invasive and
rapid way of stimulating the periosteal cambium cells to proliferate. The
advantage of the proliferated and thickened periosteal layer is 2-fold.
Firstly, the proliferated cells provide more cells for surgical or tissue
engineering strategies. Secondly, the thickened layer reduces the technical
difficulty in harvesting the periosteal cells for use, which increases the probability
of successful cambium layer, and not just fibrous layer, tissue harvest. Our
model proposes a relatively inexpensive, non-invasive, and safe way to
stimulate periosteal cell proliferation.”

According to the study authors, “ESWT stimulated periosteal
cells to differentiate down an osteogenic (bone growth) pathway.” Furthermore,
“For the large majority of samples, the (outer) fibrous layer (of the
periosteum) was structurally unchanged in the ESWT groups when compared with
controls. This provides a suturable layer for surgical use, which may be
advantageous over mesenchymal stem cells (MSCs) or other cell sources, as the
fibrous sheet can act as a delivery vehicle and can support the (adult stem)
cells. Future studies are needed to investigate the suitability of the
proliferated cells for bone – and cartilage – tissue engineering and
regenerative medicine strategies.”

Christopher M. Cashman, President and CEO of SANUWAVE, said,
“This exciting, early stage research underscores the potential of our
proprietary ESWT platform, defined as Pulsed Acoustic Cellular Expression (PACE®)
technology, as an adult stem cell proliferation and differentiation modality.
Practical applications in tissue engineering and regenerative medicine may
include, among other uses, fracture healing and autograft harvesting for bone
and cartilage regeneration, which are very large markets. PACE treatment has
the distinct clinical advantage of being noninvasive, safe and more cost
effective than current adult stem cell proliferation, harvesting and
differentiation methods. Additionally, the findings of this study build upon an
already large body of clinical evidence that demonstrates the proliferative and
proangiogenic (new blood vessel growth) effects of PACE technology.”

About SANUWAVE Health, Inc.

SANUWAVE Health, Inc. (www.sanuwave.com) is an emerging regenerative medicine
company focused on the development and commercialization of noninvasive,
biological response activating devices for the repair and regeneration of
tissue, musculoskeletal and vascular structures. SANUWAVEs portfolio of
products and product candidates activate biologic signaling and angiogenic
responses, including new vascularization and microcirculatory improvement,
helping to restore the bodys normal healing processes and regeneration.
SANUWAVE intends to apply its PACE technology in wound healing,
orthopedic/spine, plastic/cosmetic and cardiac conditions. Its lead product
candidate for the global wound care market, dermaPACE®, is CE marked for
treatment of the skin and subcutaneous soft tissue and recently completed its
highly positive pivotal Phase III, Investigational Device Exemption (IDE)
clinical trial in the U.S. for the treatment of diabetic foot ulcers. SANUWAVE
researches, designs, manufactures, markets and services its products worldwide,
and believes it has demonstrated that this technology is safe and effective in
stimulating healing in chronic conditions of the foot (plantar fasciitis) and
the elbow (lateral epicondylitis) through its U.S. Class III PMA approved
Ossatron® device, as well as stimulating bone and chronic tendonitis
regeneration in the musculoskeletal environment through the utilization of its
Ossatron, Evotron™ and orthoPACE® devices in Europe.

Posted by Sean Fenske, Editor-in-Chief, MDT

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 13, 2022
Our Pre-Post-DeviceTalks Boston episode, also MedtronicTalks replay with Gastro CMO Austin Chiang
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech